Tag Archives: stocks
Global Manufacturing Picks Up: ETFs To Watch
The month of March will be remembered for the revival in the manufacturing sector in the world’s two largest economies – the U.S. and China. While a stronger dollar and huge capex cuts by energy companies to fight back the plunge in oil prices hurt the U.S. manufacturing sector, soft demand in the wake of global growth worries can be held responsible for the overall global slowdown. However, things took a turn in March as signs of stabilization showed up. Let’s delve deeper into the data. Finally Chinese Manufacturing in Positive If we talk of manufacturing slowdown, China comes first to mind. But after posting sluggish factory output data since July 2015, the economy posted growth in March. China’s official manufacturing purchasing managers’ index (PMI) came in at 50.2 for March , which beat Reuters’ forecast of 49.3 and February’s reading of 49.0. Any reading at or above 50 suggests expansion in activity. While this official data considers larger companies, another index, namely Caixin Manufacturing PMI, considers smaller or medium-sized companies. Investors should note that the Caixin Manufacturing PMI for March also rose to 49.7 from 48.0 in February, “marking the first increase from the previous month in a year.” Improving Trend in the U.S. A five-month long losing streak also bucked the trend in the U.S. in March. The ISM manufacturing data expanded to 51.8 in March from 49.5 in February buoyed by new orders and increased output. The data came above the Wall Street Journal’s expectation of 50.5. Out of the 18 manufacturing industries, 12 reported expansion in March. What Cooks Up in the Euro Area? Coming to the Eurozone, the Markit Eurozone Manufacturing PMI came in at 51.6 in March 2016, surpassing a preliminary reading of 51.4 and 51.2 recorded in February. The reading also bettered the forecast of 51.4 . All is not well across the globe. But noticeable improvement in the big three gives us reasons to look at the below-mentioned international industrial ETFs. Global – iShares Global Industrials ETF (NYSEARCA: EXI ) The fund looks to track the S&P Global 1200 Industrials Sector Index. The $16.2 million ETF is heavy on the U.S. which takes about 53% of the basket. General Electric (NYSE: GE ) (8.62%), 3M Co. (NYSE: MMM ) (2.93%) and Siemens AG ( OTCPK:SIEGY ) (2.56%) are the top three stocks of the fund. The fund charges 48 bps in fees. It added 0.5% in the last one month (as of April 5, 2016). China – Global X China Industrial ETF (NYSEARCA: CHII ) The Global X China Industrial ETF seeks to provide investment results of the Solactive China Industrials Index. The $3.6 million fund charges 65 bps in fees. This fund is heavy on building and construction (34.4%) and machinery and equipment (31.6%) industries. The fund has exposure to about 40 stocks. CHII added 2.9% in the last one month (as of April 5, 2016). U.S. – Industrial Select Sector SPDR ETF (NYSEARCA: XLI ) This product tracks the Industrial Select Sector Index. General Electric occupies the top spot with an 11.7% allocation, while 3M, Honeywell (NYSE: HON ) and Boeing (NYSE: BA ) have a combined exposure of over 10% in the fund. XLI has garnered $6.65 billion in assets and trades in heavy volume of 13.8 million shares per day. It has a low expense ratio of 0.14%. The fund has the highest exposure to aerospace and defense (25.3%), followed by industrial conglomerates (21.6%). The product gained 2.4% in the last one month (as of April 5, 2016). Original Post
In A Beaten Down Biotech Group, These Names Are Holding Their Own
Biotech stocks have been taken to the woodshed in recent months, but the group still has several top-rated names strutting their stuff due to compelling growth prospects. While it’s best to focus on leading stocks in leading industry groups, there can be opportunities in lagging groups, especially in groups that house a lot of stocks. IBD’s biotech group is home to more than 400 stocks. It’s one of the larger groups in the database, and while there’s no shortage of stocks that have been hit hard by institutional selling in recent months, several other names are holding their own, showing relative strength. IBD 50 name Ligand Pharmaceuticals ( LGND ) has more than 85 partners and licensees in the pharmaceutical and biotech space. In February, the company reported revenue of $21.2 million, down 8% from a year earlier, but royalty revenue rose 22% to $11.5 million, helped by higher royalties from Promacta and multiple myeloma drug Kyprolis. Ligand is partnered with Novartis ( NVS ) on Promacta and with Amgen ( AMGN ) on Kyprolis. Ligand also announced a license agreement with Emergent BioSolutions ( EBS ), in which Emergent will use Ligand’s OmniAb platform to discover various antibodies. Ligand recently bought the platform from OMT, a leader in the genetic engineering of animals for the generation of human therapeutic antibodies. Emergent BioSolutions is itself another name holding up well in the biotech group. The company has a portfolio of products for biological and chemical threats, as well as emerging infectious diseases. Emergent operates a biodefense division and biosciences division, with plans to spin off the latter into a separate, publicly traded company under the name Aptevo, which will continue to focus on oncology and hematology. The distribution of Aptevo shares to Emergent shareholders is expected to be completed by the middle of the this year. Emergent’s weekly chart shows a conventional entry at 40.59, but a handle area could be in place by the end of the week that could yield an earlier entry. Elsewhere, shares of Five Prime Therapeutics ( FPRX ) have been under accumulation as they sit just below a 45.82 entry. Five Prime is scheduled to present data for its FPA144 treatment for patients with gastric cancer at the 2016 American Association for Cancer Research Annual Meeting next Monday. Five Prime isn’t profitable yet, but sales soared in 2015, thanks to a license and collaboration agreement with Bristol-Myers Squibb ( BMY ) for its FPA008 antibody. It received a $350 million upfront payment in Q4. Finally, Anika Therapeutics ( ANIK ) is a small yet compelling name in the group, with a market capitalization near $650 million. It’s showing tight action as it works on a base-on-base structure with a 47.34 entry. Anika is a provider of therapeutic pain management solutions. Earnings and sales growth accelerated nicely in the latest reported quarter, up 41% and 33% respectively. Image provided by Shutterstock .